|
371 Contractors to
be hit by significant drop in income Pharmacy
contractors will be hit by significant and unexpected reductions in income
over the next few months following the latest quarterly revision of reimbursement
prices for generic medicines
PJ 2007;279:371
Full Text
371 Angry reaction across the board
to latest Category M price changes Individual
contractors, multiples and wholesalers alike have reacted angrily to
the announcement that substantial reductions have been made to Category
M prices in the October Drug Tariff
PJ 2007;279:371
Full Text
372 CCA criticises lack of
transparency in fees rationale The Company Chemists' Association believes that the Royal Pharmaceutical Society's powers to increase pharmacist retention fees should come with a “responsibility to act reasonably and proportionately”
PJ 2007;279:372
Full Text
372 Anti-violence initiatives to receive DoH
funds Initiatives to tackle violence against NHS staff are to benefit from £97m of extra funding, the Department of Health announced last week
PJ 2007;279:372
Full Text
372 NPA says pharmacists will need help with
EU prescriptions Pharmacists will need to be given
detailed guidance if they are to be able to dispense prescriptions from doctors
in Europe, as well as those written by UK prescribers
PJ 2007;279:372
Full Text
372 Patient involvement forum to be replaced
by new body Consultation has started on the planned
powers of local involvement networks (LINks), which are to replace patient and
public involvement forums in England. The role of LINks will be to hold commissioners
and providers of health and social care, including community pharmacists and
pharmacy owners, to public account
PJ 2007;279:372
Full Text
373 War of words breaks out
over rural Scottish services NHS boards should
consult local residents to establish their views before approving pharmacy applications,
BMA Scotland said this week. The association is concerned that dispensing doctors
are under threat by the introduction of new pharmacies into small rural communities
in Scotland
PJ 2007;279:373
Full Text
373 Decongestant pack size limits proposed Proposals
for statutory limits to the size of over-the-counter packs of products that contain
pseudoephedrine or ephedrine have been put out for consultation by the Medicines
and Healthcare products Regulatory Agency
PJ 2007;279:373
Full Text
373 PSNC-NPA merger ruled out Merging
the National Pharmacy Association and the Pharmaceutical Services Negotiating
Committee into a single organisation has been ruled out
PJ 2007;279:373
Full Text
373 No new vet medicine class Proposals
for a new category of veterinary medicine have been dropped by the Veterinary
Medicines Directorate after receiving almost no support in a consultation earlier
this year
PJ 2007;279:373
Full Text
373 Pharmacy inquiry board Robert
Dingwall, director of the Institute for Science and Society, University of Nottingham,
Dame Jill Macleod Clark, deputy dean of the University of Southampton's faculty
of medicine, health and biological science and Peter Owen, chief executive of
the Institute of Chartered Accountants, have been appointed to advise Nigel Clarke
as he conducts his inquiry into a professional body for pharmacy
PJ 2007;279:373
Full Text
373 MRSA pilot study in Scotland NHS
Quality Improvement Scotland has recommended that a pilot study be set up in
a number of hospitals within NHS Scotland to assess whether screening for meticillin-resistant
Staphylococcus aureus in all patients who are admitted is effective in reducing
MRSA infections
PJ 2007;279:373
Full Text
374 Software solutions could
couple symptoms with drug side effects Computer
software could be used to discover whether a patient's reported symptoms may
be linked to a side effect of their medication, according to Liverpool GP and
GP trainer David Orlans
PJ 2007;279:374
Full Text
374 Better education around drug costs needed
for doctors Doctors need better education about
the cost of drugs, and where to access cost information, say researchers
PJ 2007;279:374
Full Text
374 NICE to re-examine erlotinib following appeal Erlotinib
(Tarceva, Roche) is to be re-examined by a National Institute for Health and
Clinical Excellence appraisal committee after a NICE appeal board overruled the
institute's original decision not to recommend the drug for the treatment of
non-small cell lung cancer on cost-effectiveness grounds
PJ 2007;279:374
Full Text
374 Benefit of bath emollients is questionable,
DTB says Bath emollients are of dubious
benefit in the treatment of patients with atopic eczema, the latest issue of
the Drug and Therapeutics Bulletin concludes
PJ 2007;279:374
Full Text
375 Academic super-trust for
London Imperial College London is to be at the
helm of a new NHS super-trust, following the union of two of London's largest
hospitals this week. Hammersmith Hospitals NHS Trust and St Mary's NHS Trust
have merged, and existing links with Imperial College have been strengthened,
to form Imperial College Healthcare NHS Trust
PJ 2007;279:375
Full Text
375 Workspace research starts Researchers at Swansea University have been awarded £100,000 to study, among other things, how community pharmacists' views of their workspaces impact on their working practices
PJ 2007;279:375
Full Text
375 CPPE prepares allergy course The
Centre for Pharmacy Postgraduate Education is developing a qualification on allergies
to allow pharmacists to develop services for identifying allergies or intolerances
through a 30-minute consultation with the patient, then providing confirmation
with an appropriate blood test
PJ 2007;279:375
Full Text
376 Strategy launched to improve
clinical skills of pharmacists and others in Scotland Pharmacists,
GPs and community health teams in Scotland will benefit from a clinical skills
strategy launched last week by health minister Nicola Sturgeon
PJ 2007;279:376
Full Text
376 Ethical dilemmas set to grow with complex
patient care Pharmacists will likely face greater
ethical dilemmas affecting relationships with patients and professional colleagues
as they become involved with more complex patient care, according to Ann Lewis,
former Secretary and Registrar of the Royal Pharmaceutical Society
PJ 2007;279:376
Full Text
376 Lloydspharmacy launches breast cancer detection
campaign A campaign to increase awareness of breast
cancer and its detection has been launched this week by Lloydspharmacy
PJ 2007;279:376
Full Text
376 Continuing trastuzumab after relapse improves
survival in advanced breast cancer Continuing treatment
with trastuzumab (Herceptin) improves survival in women with HER-2 positive advanced
breast cancer that has relapsed, according to a study reported last week at the
European Cancer Conference in Barcelona
PJ 2007;279:376
Full Text
376 Acupuncture reasonable Acupuncture
appears to be a reasonable therapy option for patients with knee osteoarthritis
when lifestyle measures and paracetamol are insufficient or contraindicated,
the latest issue of the Drug and Therapeutics Bulletin concludes
PJ 2007;279:376
Full Text
376 Thiazolidinedione safety Patients
with prediabetes or type 2 diabetes given thiazolidinediones (either rosiglitazone
or pioglitazone) have an increased risk of developing congestive heart failure
but not an increased risk of cardiovascular death, compared with controls, data
from a new meta-analysis indicate
PJ 2007;279:376
Full Text
376 Hepatitis C tests Free
hepatitis C tests were available to members of the public at a Nottingham branch
of Boots this week to coincide with World Hepatitis Awareness Day on 1 October
2007
PJ 2007;279:376
Full Text
376 Clinical vision for NHS Access
to skilled pharmacists is one of the requirements set out by the NHS Confederation
and the Joint Medical Consultative Council as part of their design principles
for a better, more innovative NHS
PJ 2007;279:376
Full Text
377 Pharmacist interventions
improve HbA1c levels, not other outcomes Pharmacist
interventions can lead to reduced HbA1c levels for diabetes patients, but other
benefits are not clear, the authors of a meta-analysis conclude
PJ 2007;279:377
Full Text
377 Agitation associated with Alzheimer's not
relieved by donepezil Donepezil is not an effective
treatment for agitation in people with Alzheimer's disease, a study published
this week suggests
PJ 2007;279:377
Full Text |
The
Pharmaceutical Journal